Beacon Pharmaceuticals Limited (BPL) has launched Pandovir 100, a broad-spectrum antiviral medicine, for the treatment of severe Covid-19 cases under the generic of Remdesivir.
The BPL launched the generic version of Remdesivir in august in view to provide drug or treatment of Cvid 19 patient in August.
Directorate General of Drug Administration (DGDA) considered it as an Emergency Use Authorization (EUA) for the patients who are hospitalized with probable or laboratory-confirmed case of SARS-CoV-2.
The drugs will also be used for the patients who require supplementary oxygen, mechanical ventilation or extracorporeal membrane oxygenation. Specially, Remdesivir is only authorized for adult and pediatric patients.
The medicine will be available in the market in a single strength –100mg –injection that will open a new horizon for treating the severely ill Covid-9 patients.
BPL already started to ship the product to 21 destinations while other 18 countries, including some in Latin America, the Middle East and Africa, are currently negotiating for supply.
While the pandemic has had an adverse impact on other sectors, it has come as a blessing for the pharmaceutical industry as local drug makers used it to demonstrate their efficiency and quality to the international market.
It is really a benefit for the country’s image to be the first to provide Remdesivir globally.